Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor ? transgenic mice
- 1 December 2001
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (12) , 2888-2898
- https://doi.org/10.1002/1529-0131(200112)44:12<2888::aid-art477>3.0.co;2-3
Abstract
Rheumatoid arthritis is a prototype of a destructive inflammatory disease. Inflammation triggered by the overexpression of tumor necrosis factor alpha (TNFalpha) is a driving force of this disorder and mediates tissue destruction. Since matrix metalloproteinases (MMPs) are among the molecules activated by TNFalpha, we hypothesized that overexpression of their natural inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1), in TNFalpha transgenic mice could inhibit the development of destructive arthritis. Systemic treatment was carried out by replication-defective adenoviral vectors for TIMP-1, beta-galactosidase, or phosphate buffered saline (PBS), which were applied once at the onset of arthritis. Clinical, serologic, radiologic, and histologic outcomes were assessed 18 days after the treatment. The AdTIMP-1 group showed significantly reduced paw swelling and increased grip strength compared with the 2 control groups, whereas total body weight, TNFalpha, and interleukin-6 levels were similar in all 3 groups. Radiographic assessment revealed a significant reduction of joint destruction in the AdTIMP-1 group; this was confirmed by histologic analyses showing reduced formation of pannus and erosions in the AdTIMP-1 group compared with the AdLacZ and PBS control groups. The formation of arthritis-specific autoantibodies to heterogeneous nuclear RNP A2 was not observed in the AdTIMP-1 group but was present in the 2 control groups. These results indicate a central role of MMPs in TNFalpha-mediated tissue damage in vivo and a promising therapeutic role for TIMP-1.Keywords
This publication has 49 references indexed in Scilit:
- Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase‐inhibitorBritish Journal of Pharmacology, 2000
- Bone Resorption by OsteoclastsScience, 2000
- Expression of matrix metalloproteinase 9 (96‐kd gelatinase B) in human rheumatoid arthritisArthritis & Rheumatism, 1996
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activityArthritis & Rheumatism, 1995
- The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF In Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality In VivoCytokine, 1995
- Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?Arthritis & Rheumatism, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex.Journal of Clinical Investigation, 1992
- Hand Radiography of 200 Patients with Rheumatoid Arthritis Repeated after an Interval of One YearScandinavian Journal of Rheumatology, 1987